Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACET
stocks logo

ACET

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.203
-36.46%
--
--
-0.175
-43.55%
--
--
-0.180
-47.06%
Estimates Revision
The market is revising No Change the revenue expectations for Adicet Bio, Inc. (ACET) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.95%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-10.69%
In Past 3 Month
Stock Price
Go Down
down Image
-22.95%
In Past 3 Month
Wall Street analysts forecast ACET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACET is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast ACET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACET is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.555
sliders
Low
5.00
Averages
7.00
High
9.00
Current: 0.555
sliders
Low
5.00
Averages
7.00
High
9.00
H.C. Wainwright
Robert Burns
Buy
upgrade
$4 -> $9
2025-11-07
Reason
H.C. Wainwright
Robert Burns
Price Target
$4 -> $9
2025-11-07
upgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Adicet Bio to $9 from $4 and keeps a Buy rating on the shares. The firm views ADI-001's profile as "extremely attractive" in both lupus nephritis and systemic lupus erythematosus.
H.C. Wainwright
Robert Burns
initiated
$4
2025-07-23
Reason
H.C. Wainwright
Robert Burns
Price Target
$4
2025-07-23
initiated
Reason
H.C. Wainwright analyst Robert Burns assumed coverage of Adicet Bio with a Buy rating and $4 price target. The firm says preliminary data for ADI-270 in clear cell renal cell carcinoma is expected in the second half of 2025. It views the readout as a "partially risk-mitigated data catalyst" and says Adicet's autoimmune program is a "free call option."
Guggenheim
Yatin Suneja
Strong Buy
Reiterates
$7
2025-03-21
Reason
Guggenheim
Yatin Suneja
Price Target
$7
2025-03-21
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Reni Benjamin
Hold
Reiterates
n/a
2025-03-07
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
n/a
2025-03-07
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-07
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-07
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-02-27
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-02-27
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Adicet Bio Inc (ACET.O) is -0.73, compared to its 5-year average forward P/E of -3.32. For a more detailed relative valuation and DCF analysis to assess Adicet Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.32
Current PE
-0.73
Overvalued PE
-0.32
Undervalued PE
-6.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.14
Undervalued EV/EBITDA
-2.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
50.42
Current PS
0.00
Overvalued PS
150.77
Undervalued PS
-49.93
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ACET News & Events

Events Timeline

(ET)
2025-11-05
16:04:17
Adicet Bio announces Q3 earnings per share of 29 cents, falling short of consensus estimate of 32 cents.
select
2025-11-05
16:03:48
Adicet Bio Announces Q3 Earnings Per Share, Meeting Consensus of 32 Cents
select
2025-10-16 (ET)
2025-10-16
07:04:00
Adicet Bio administers first dose to patient in ADI-001 trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-29Newsfilter
Adicet Bio Grants New Employee 20,600 Stock Options at $0.65 Each
  • Employee Incentive Program: On November 28, 2025, Adicet Bio granted a new employee 20,600 non-qualified stock options with an exercise price of $0.65 per share, reflecting the company's commitment to talent acquisition and aiming to enhance team stability and innovation capacity.
  • Vesting Mechanism: One-fourth of the options will vest on the employee's one-year anniversary, with the remaining three-fourths vesting in 36 equal monthly installments, which not only incentivizes long-term retention but also enhances the company's overall talent attraction.
  • Compliance Assurance: The award was granted under Adicet's 2022 Inducement Plan, ensuring adherence to Nasdaq listing rules, which demonstrates the company's commitment to compliance and transparency in talent management.
  • Strategic Development Direction: By implementing this new talent incentive mechanism, Adicet Bio aims to accelerate the clinical advancement of its proprietary gamma delta T cell therapies, thereby positioning itself more favorably in the treatment of autoimmune diseases and cancer.
[object Object]
Preview
9.5
11-19NASDAQ.COM
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday

  • Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.

  • Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.

  • Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.

  • Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.

[object Object]
Preview
6.0
10-09NASDAQ.COM
Guggenheim Upholds Buy Rating for Adicet Bio (ACET)

  • Analyst Recommendation: Guggenheim has maintained a Buy recommendation for Adicet Bio (NasdaqGM:ACET) with a projected price target of $6.12/share, indicating a potential upside of 557.78% from its current price of $0.93/share.

  • Fund Sentiment and Ownership: There are 72 funds reporting positions in Adicet Bio, with a decrease of 18.18% in ownership over the last quarter. Notable shareholders include Orbimed Advisors and Tang Capital Management, while Goldman Sachs has reduced its stake by 1.72%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adicet Bio Inc (ACET) stock price today?

The current price of ACET is 0.555 USD — it has increased 3.35 % in the last trading day.

arrow icon

What is Adicet Bio Inc (ACET)'s business?

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

arrow icon

What is the price predicton of ACET Stock?

Wall Street analysts forecast ACET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACET is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adicet Bio Inc (ACET)'s revenue for the last quarter?

Adicet Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Adicet Bio Inc (ACET)'s earnings per share (EPS) for the last quarter?

Adicet Bio Inc. EPS for the last quarter amounts to -0.29 USD, decreased -14.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Adicet Bio Inc (ACET)'s fundamentals?

The market is revising No Change the revenue expectations for Adicet Bio, Inc. (ACET) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.95%.
arrow icon

How many employees does Adicet Bio Inc (ACET). have?

Adicet Bio Inc (ACET) has 152 emplpoyees as of December 05 2025.

arrow icon

What is Adicet Bio Inc (ACET) market cap?

Today ACET has the market capitalization of 85.06M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free